News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theraclone Sciences, Inc. Initiates Phase 2 Viral Challenge Clinical Study of Therapeutic Antibody for the Treatment of Influenza A


10/25/2012 9:51:57 AM

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the initiation of a Phase 2 clinical study of TCN-032 in a viral challenge model. TCN-032 is a broadly protective and fully human monoclonal antibody being developed for the treatment of influenza A infections.

Read at BioSpace.com

comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES